Abstract: In recent years, there has been a rapid increase in the worldwide population of individuals with diabetes, and the prevalence of diabetes among adults in China has reached 11. 9%. Medications play a pivotal role in the management of diabetes. Glucokinase activators (GKA) have garnered considerable attention in the research and development of novel medications for the treatment of type 2 diabetes, owing to their ability to target glucokinase, a key regulator of glucose homeostasis in hepatic cells. An examination of the current status of patents concerning glucokinase activators can offer valuable scientific and technological insights to inform decision-making and drive the progress of industries associated with glucokinase activators. This study utilizes the patent metrology method, drawing on the Derwent patent database and Cortellis database as primary data sources, to analyze patent application trends, patent distribution, patent applicants, their pharmaceutical products, patent technology composition, hotspots, and the technological development trajectory. The findings indicate that GKA technology is in a state of ongoing development, with the United States and Japan emerging as the main regions for its distribution. Roche, AstraZeneca, Pfizer, and Hualing Pharmaceutical Company have filed the highest number of patent applications. The patented technology encompasses seven key areas, including drug structure, drug dosage form, drug compatibility, pharmaceutical chemistry, and disease treatment. Based on the analysis results, several recommendations are put forward in the field of glucokinase activators in China, aiming to provide references for future patent application strategies and innovative product research and development.

Key words: Glucokinase Activator, GKA, Patent Analysis, Patent Layout